<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03642795</url>
  </required_header>
  <id_info>
    <org_study_id>PHRCI/2016/CGV-01</org_study_id>
    <nct_id>NCT03642795</nct_id>
  </id_info>
  <brief_title>Validation of the French Version of the CQR (Compliance Questionnaire Rheumatology)</brief_title>
  <acronym>CQR-F</acronym>
  <official_title>Validation of the French Version of the CQR (Compliance Questionnaire Rheumatology): Specific Tool for Evaluation of Observance of Rheumatology Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nīmes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nīmes</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to develop a French language version of the
      Compliance-Questionnaire-Rheumatology for use in French and Francophone rheumatology services
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2020</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Test-retest agreement of French translation of the Compliance Questionnaire Rheumatology questionnaire</measure>
    <time_frame>3 hours</time_frame>
    <description>Intraclass correlation and Kappa coefficient of 2 evaluations taken 3 hours apart</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Structural validity of French translation of the Compliance Questionnaire Rheumatology questionnaire</measure>
    <time_frame>Baseline</time_frame>
    <description>Principal component analysis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Validation of the Compliance Questionnaire Rheumatology against gold standard (erythrocyte methotrexate polyglutamates (MTX PGs) concentration)</measure>
    <time_frame>Baseline</time_frame>
    <description>CQR ≥80% (observant) vs MTX PGs level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of missing responses to each question of French translation of Compliance Questionnaire Rheumatology</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of questionnaires with at least 1 missing item</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Validation of the short form of the French Compliance Questionnaire Rheumatology</measure>
    <time_frame>Baseline</time_frame>
    <description>5-item questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare French Compliance Questionnaire Rheumatology results against general questionnaire Morisky Medication Adherence Scale (MMAS-8)</measure>
    <time_frame>Baseline</time_frame>
    <description>Sensitivity and specificity compared against MTX PGs level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sex of observant versus non-observant patients</measure>
    <time_frame>Month 1</time_frame>
    <description>male/female</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Age of observant versus non-observant patients</measure>
    <time_frame>Month 1</time_frame>
    <description>years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>education level of observant versus non-observant patients</measure>
    <time_frame>Month 1</time_frame>
    <description>school graduation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>profession of observant versus non-observant patients</measure>
    <time_frame>Month 1</time_frame>
    <description>name of the profession</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>marital status of observant versus non-observant patients</measure>
    <time_frame>Month 1</time_frame>
    <description>Married, single, divorced, widowed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number patients observing medication</measure>
    <time_frame>Month 1</time_frame>
    <description>Blood MTX PG concentration nmol/L by LC-MS/MS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life in observant versus non-observant patients</measure>
    <time_frame>Month 1</time_frame>
    <description>Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life in observant versus non-observant patients</measure>
    <time_frame>Month 1</time_frame>
    <description>Euroqol 5 dimension 3 level questionnaire (EQ5D-3L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional incapacity in observant versus non-observant patients</measure>
    <time_frame>Month 1</time_frame>
    <description>Health Assessment Questionnaire (HAQ)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain experience in observant versus non-observant patients</measure>
    <time_frame>Month 1</time_frame>
    <description>Pain Catastrophizing Scale (PCS-CF)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive representations of medication in observant versus non-observant patients</measure>
    <time_frame>Month 1</time_frame>
    <description>Beliefs about Medicines Questionnaire</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Rheumatoid Polyarthritis</condition>
  <arm_group>
    <arm_group_label>Patients with rheumatoid polyarthritis</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire</intervention_name>
    <description>Patients are asked to complete several questionnaires</description>
    <arm_group_label>Patients with rheumatoid polyarthritis</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with rheumatoid polyarthritis as defined by the ACR-EULAR 2010 criteria, treated
        orally or subcutaneously with MTX for at least 3 months being followed in the rheumatology
        department of Montpellier, Toulouse, Bordeaux or Nîmes hospitals.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patient must have given their free and informed consent and signed the consent
             form

          -  The patient must be a member or beneficiary of a health insurance plan

          -  The patient is at least 18 years old

          -  The patient has rheumatoid polyarthritis as defined by the ACR-EULAR 2010 criteria,
             treated orally or subcutaneously with MTX for at least 3 months. Other treatments at
             the same time are authorized

        Exclusion Criteria:

          -  The subject is participating in an interventional study, or is in a period of
             exclusion determined by a previous study

          -  The subject refuses to sign the consent

          -  It is impossible to give the subject informed information

          -  The patient is under safeguard of justice or state guardianship

          -  The subject has a contraindication to taking methotrexate (including a patient with a
             desire to become pregnant).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Cécile Gaujoux Viala, MD</last_name>
    <phone>04 66 68 31 20</phone>
    <email>cecile.gaujoux.viala@chu-nimes.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Christophe Richez, MD</last_name>
      <email>christophe.richez@chu-bordeaux.fr</email>
    </contact>
    <investigator>
      <last_name>Christophe Richez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Jacques Morel, MD</last_name>
      <email>j-morel@chu-montpellier.fr</email>
    </contact>
    <investigator>
      <last_name>Jacques Morel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Nimes</name>
      <address>
        <city>Nîmes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Anissa Megzari</last_name>
      <phone>04.66.68.42.36</phone>
      <email>drc@chu-nimes.fr</email>
    </contact>
    <investigator>
      <last_name>Cécile Gaujoux Viala</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Toulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31300</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Arnaud Constantin</last_name>
      <email>arnaud.constantin@univ-tlse3.fr</email>
    </contact>
    <investigator>
      <last_name>Arnaud Constantin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>November 14, 2017</study_first_submitted>
  <study_first_submitted_qc>August 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 22, 2018</study_first_posted>
  <last_update_submitted>June 12, 2020</last_update_submitted>
  <last_update_submitted_qc>June 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

